诺如病毒
鼠诺如病毒
病毒学
效价
免疫系统
抗体
免疫学
接种疫苗
医学
CD8型
免疫球蛋白A
免疫球蛋白G
生物
中和抗体
微生物学
肠粘膜
免疫
细胞毒性T细胞
病毒
信使核糖核酸
中和
核糖核酸
免疫
作者
Arya Ökten,Renata B. Filler,Justin L. Kung,Zhenhao Fang,Brieyanna C. McWilliams,Jenna E. Muscat-Rivera,Michael S. Kegel,Ilze M. Olivi Gomes,Madeleine C. Mankowski,Ashwin N. Skelly,Jilian R. Melamed,Timothy J. Nice,Sanghyun Lee,Megan T. Baldridge,Thomas J. Smith,Christiane E. Wobus,Stephanie C. Eisenbarth,Adam Williams,Leonid Serebryannyy,Daniel C. Douek
标识
DOI:10.1126/scitranslmed.aeb4878
摘要
Human norovirus is the leading cause of viral gastroenteritis, yet effective vaccines and therapeutics remain elusive. Using murine norovirus as a model, we found that mucosal immunoglobulin A (IgA) is both necessary and sufficient for protection against infection, whereas CD8 + T cells are dispensable. Robust intestinal IgA production requires at least 4 weeks of enteric infection, consistent with kinetics of human norovirus RNA clearance. Systemic vaccination elicits high titers of neutralizing serum IgG but fails to prevent enteric norovirus infection, phenocopying a recent human norovirus vaccine failure. In contrast, prophylactic delivery of dimeric anti-norovirus IgA via mRNA lipid nanoparticles confers sterilizing immunity. Together, these findings define a critical role for mucosal IgA in norovirus protection and identify IgA-based treatments as a therapeutic approach for human norovirus.
科研通智能强力驱动
Strongly Powered by AbleSci AI